[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"serum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:serum":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100599849","this-study-evaluates-the-alpco-syphilis-t-and-syphilis-nt-clia-kits-for-detecting-syphilis-antibodies-in-serum-and-plasma-samples-from-at-risk-hiv-positive-pregnant-and-healthy-individuals-will-assess-assay-performance-versus-established-comparator-tests-100599849",false,"NCT07089836","This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.","ALPCO Syphilis-T and Syphilis-NT CLIA Kits: Detection of Antibodies to Treponema Pallidum and Against Lipoidal Antigens in Human Serum and Plasma","Inclusion Criteria:\n\n* Male, Female, or Other(s)\n* Patients undergoing routine syphilis testing (asymptomatic at risk, suspected with symptoms, prior history of syphilis, high risk for syphilis) or previously diagnosed with syphilis through a test performed in an accredited laboratory.\n* Participants must be willing to provide the required blood samples for the clinical study, in addition to any samples requested by their physician.\n* Pregnant individuals and children (under 22): 1 clinical study tube of blood.\n* All other participants (excluding pregnant individuals and children): 2 clinical study tubes of blood.\n* Participants must be able and willing to sign the informed consent form (ICF).\n* Participants aged 13 to 17 will be asked to sign an assent form. Written parental or guardian consent will also be required prior to enrollment. The assent form will use age-appropriate language and be reviewed with the participant before any procedures.\n\nExclusion Criteria:\n\n* Patients currently being treated with antibiotics or completed a course of antibiotics within the past 30 days\n* Patients with pre-existing conditions that would make blood collection difficult or harmful\n* If the samples are not collected in strict accordance with the established sampling protocol, as determined by the study team.\n* Any medical, psychological, or social condition that, in the judgment of the investigator, could interfere with the participant's ability to comply with study requirements, or pose a risk to their safety, or compromise the integrity of the study.",true,"ALL","13 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","This study will evaluate the clinical performance of two investigational diagnostic kits developed by ALPCO: the Syphilis-T CLIA Kit and the Syphilis-NT CLIA Kit. These kits are designed to detect antibodies to Treponema pallidum and non-treponemal lipoidal antigens, respectively, in human serum and plasma using the automated KleeYa platform. The study will collect and analyze blood samples from individuals suspected of having syphilis, those at high risk, HIV-positive patients, pregnant individuals, and healthy controls. The aim is to determine the kits' Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) compared to established reference assays.",[25,26,27,28,29,30,31],"Treponema Pallidum","Treponema Pallidum Infection","Syphilis Infection","Serum","Plasma","Blooddraw","Sexually Transmitted Infection (STI)",[33,34,35,36,37,38,39,40,41,42],"Non Treponema","Treponema","Syphilis","Sample Collection","Treponema pallidum","Non-treponemal test","Chemiluminescent immunoassay","HIV-positive","Pregnant women","Blood sample collection","RECRUITING","2026-02-09",{"date":46,"type":47},"2026-02-11","ACTUAL",{"date":49,"type":47},"2025-12-10",{"date":51,"type":21},"2026-07",{"name":53,"class":54},"American Laboratory Products Company","INDUSTRY",6,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100599524","neutralizing-power-of-serum-antibodies---2-100599524","NCT07085611","Neutralizing Power of Serum Antibodies - 2","Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)","PNAS-2","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Patients receiving or scheduled to receive anti-SARS-CoV-2 and\u002For anti-MPXV vaccines or monoclonal antibodies\n* Patients have provided written informed consent\n\nExclusion Criteria:\n\n* Persons under guardianship or curatorship\n* Persons under legal protection,\n* Persons persons deprived of liberty\n* Persons not affiliated to a social security scheme\n* Pregnant or breastfeeding women","18 Years",{"count":66,"type":21},30,"INTERVENTIONAL",[69],"NA","Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.",[72,73,74,75,28,76],"COVID-19","SARS-CoV-2 Viraemia","Monkey Pox","Vaccination","Mucosal Immunity",[78,79,80,75,28,81],"Neutralizing antibodies","SARS-CoV-2","Monkeypox","Mucosal immunity","2025-12-12",{"date":84,"type":47},"2025-12-19",{"date":86,"type":47},"2025-08-22",{"date":88,"type":21},"2035-07-11",{"name":90,"class":91},"Centre Hospitalier Régional d'Orléans","OTHER",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":92},"100604793","endocan-and-copeptin-serum-levels-in-preterm-neonates-with-respiratory-distress-syndrome-100604793","NCT07154134","Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome","Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Prematurity.\n* Gestational age between 28 and 36 weeks.\n* Suffering from respiratory distress syndrome.\n\nExclusion Criteria:\n\n* Intrauterine growth restriction (IUGR).\n* Hypoxic ischemic encephalopathy.\n* Multiple congenital anomalies.\n* Chromosomal abnormalities.\n* Preterm less than 28 weeks.\n* Neonates with a maternal history of chorioamnionitis (early sepsis).\n* Infant of diabetic mother.\n* Prelabor rupture of membranes (PROM)\\> 2 hours.","28 Weeks","36 Weeks",{"count":103,"type":21},40,"This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.",[106,107,28,108,109],"Endocan","Copeptin","Preterm Neonates","Respiratory Distress Syndrome","2025-08-27",{"date":112,"type":47},"2025-09-04",{"date":114,"type":47},"2025-07-10",{"date":116,"type":21},"2025-11-01",{"name":118,"class":91},"Tanta University"]